Comment le ratio PS de BLE se compare-t-il à celui de ses pairs ?

BLE offre un bon rapport qualité-prix en fonction de son ratio Price-To-Sales ( 1.4 x) par rapport à la moyenne des pairs ( 7.8 x).

Comment le ratio PS de BLE se compare-t-il à celui d'autres entreprises du secteur DE Biotechs ?

BLE offre un bon rapport qualité-prix en fonction de son ratio Price-To-Sales ( 1.4 x) par rapport à la moyenne du secteur German Biotechs ( 12.6 x).

Quel est le ratio PS de BLE par rapport à son ratio équitable PS? Il s'agit du ratio PS attendu, compte tenu des prévisions de croissance des bénéfices de l'entreprise, des marges bénéficiaires et d'autres facteurs de risque.

BLE présente un bon rapport qualité-prix en fonction de son ratio Price-To-Sales ( 1.4 x) par rapport au ratio équitable Price-To-Sales estimé ( 3.2 x).

Quel est le juste prix de BLE si l'on considère ses flux de trésorerie futurs ? Pour cette estimation, nous utilisons un modèle d'actualisation des flux de trésorerie.

BLE ( €0.33 ) se négocie en dessous de notre estimation de la [[juste valeur]] ( €8.35 )

Quelles sont les prévisions à 12 mois des analystes et avons-nous une confiance statistique dans l'objectif de prix du consensus ?

Le prix cible est supérieur de plus de 20 % au prix actuel de l'action, mais les analystes ne se situent pas dans une fourchette d'accord statistiquement fiable.

bluebird bio (MUN:BLE) - Cours de l'action, nouvelles et analyse

BLE Aperçu des actions

bluebird bio, Inc. est une société de biotechnologie qui recherche, développe et commercialise des thérapies géniques pour le traitement de maladies génétiques graves aux États-Unis. Plus de détails

BLE analyse fondamentale
Score flocon de neige
Évaluation	5/6
Croissance future	2/6
Performances passées	0/6
Santé financière	0/6
Dividendes	0/6

Récompenses

Se négocie à 96% en dessous de notre estimation de sa juste valeur

Les revenus devraient augmenter 41.53% par an

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

A moins d'un an de piste de trésorerie

Capitaux propres négatifs

Cours de l'action très volatil au cours des 3 derniers mois

+ 2 plus de risques

bluebird bio, Inc. Concurrents

2invest

XTRA:2INV

€62.7m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Medigene

XTRA:MDG1

€17.4m

co.don

XTRA:CNW

€6.5m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour bluebird bio
Historique des cours de bourse
Prix actuel de l'action	US$0.33
Plus haut sur 52 semaines	US$4.75
Plus bas sur 52 semaines	US$0.29
Bêta	0.80
1Variation sur 1 mois	-28.58%
Variation sur 3 mois	-41.05%
Variation sur 1 an	n/a
3Variation sur 3 ans	-96.37%
Variation sur 5 ans	n/a
Évolution depuis l'introduction en bourse	-97.98%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	BLE	DE Biotechs	DE Marché
7D	15.0%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de BLE par rapport au secteur German Biotechs.

Rendement vs marché: Données insuffisantes pour déterminer la performance de BLE par rapport au marché German.

Volatilité des prix

Is BLE's price volatile compared to industry and market?
BLE volatility
BLE Average Weekly Movement	13.1%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Cours de l'action stable: Le cours de l'action de BLE a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de BLE a diminué de 21% à 13% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1992	282	Andrew Obenshain	www.bluebirdbio.com

bluebird bio, Inc. est une société de biotechnologie qui recherche, développe et commercialise aux États-Unis des thérapies géniques pour le traitement de maladies génétiques graves. Les produits candidats de la société pour les maladies génétiques graves comprennent ZYNTEGLO (betibeglogene autotemcel) pour le traitement de la ß-thalassémie dépendante des transfusions ; lovotibeglogene autotemcel pour le traitement de la drépanocytose (SCD) ; et SKYSONA (elivaldogene autotemcel) pour le traitement de l'adrénoleucodystrophie cérébrale. Ses programmes de développement clinique comprennent HGB-205, HGB-206 et HGB-210 pour évaluer la sécurité et l'efficacité de lovo-cel dans le traitement des patients atteints de DSC ; et HGB-204, HGB-205, HGB-207 et HGB-212 pour évaluer la sécurité et l'efficacité de beti-cel dans le traitement des patients atteints de ß-thalassémie.

bluebird bio, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de bluebird bio se comparent-ils à sa capitalisation boursière ?
BLE statistiques fondamentales
Capitalisation boursière	€68.67m
Bénéfices(TTM)	-€279.50m
Recettes(TTM)	€50.70m

1.4x

Ratio P/S

-0.2x

Ratio P/E

Le site BLE est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
BLE compte de résultat (TTM)
Recettes	US$53.12m
Coût des recettes	US$78.78m
Marge brute	-US$25.66m
Autres dépenses	US$267.16m
Les revenus	-US$292.82m

Derniers bénéfices déclarés

Sep 30, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-1.51
Marge brute	-48.31%
Marge bénéficiaire nette	-551.25%
Ratio dettes/capitaux propres	-1,394.4%

Quelles ont été les performances à long terme de BLE?

Voir les performances historiques et les comparaisons

BLE Aperçu des actions

Récompenses

Analyse des risques

bluebird bio, Inc. Concurrents

XTRA:2INV

€62.7m

XTRA:HPHA

€105.8m

XTRA:MDG1

€17.4m

XTRA:CNW

€6.5m

Historique des prix et performances

Nouvelles et mises à jour récentes

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

New major risk - Negative shareholders equity

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Revenue and earnings growth

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 41% undervalued after recent price drop

Bluebird Bio, Inc. Announces FDA Approval of LYFGENIA™? (Lovo-Ccel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

Now 24% undervalued

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.94 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Insider selling

President recently sold €54k worth of stock

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$1.36 loss in 2Q 2022)

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

First quarter 2023 earnings released: EPS: US$0.21 (vs US$1.66 loss in 1Q 2022)

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.94 loss per share (vs US$2.23 loss in 3Q 2021)

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold €78k worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold €94k worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer